Invesco Ltd. Sells 323,850 Shares of Bioventus Inc. (NYSE:BVS)

Invesco Ltd. cut its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 94.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,096 shares of the company's stock after selling 323,850 shares during the period. Invesco Ltd.'s holdings in Bioventus were worth $201,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Plato Investment Management Ltd bought a new stake in shares of Bioventus during the fourth quarter valued at approximately $38,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Bioventus during the 4th quarter valued at about $75,000. Quantbot Technologies LP acquired a new position in Bioventus in the fourth quarter worth about $103,000. Arizona State Retirement System bought a new stake in Bioventus in the fourth quarter valued at $109,000. Finally, HighTower Advisors LLC lifted its holdings in Bioventus by 11.3% during the 4th quarter. HighTower Advisors LLC now owns 13,617 shares of the company's stock valued at $143,000 after purchasing an additional 1,380 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bioventus

In related news, CFO Mark Leonard Singleton sold 3,875 shares of the company's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total transaction of $29,333.75. Following the completion of the sale, the chief financial officer now owns 141,088 shares of the company's stock, valued at $1,068,036.16. This represents a 2.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Anthony D'adamio sold 4,380 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares in the company, valued at $1,204,233.82. This represents a 3.57 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,208 shares of company stock valued at $226,138. 32.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BVS has been the topic of several research analyst reports. Canaccord Genuity Group restated a "buy" rating and set a $15.00 target price on shares of Bioventus in a report on Monday, March 17th. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the company a "buy" rating in a report on Wednesday.

Bioventus Stock Up 1.0 %

Shares of Bioventus stock traded up $0.07 during trading on Friday, reaching $6.87. The stock had a trading volume of 102,000 shares, compared to its average volume of 451,203. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The company has a market capitalization of $562.96 million, a price-to-earnings ratio of -11.26 and a beta of 0.95. Bioventus Inc. has a 52 week low of $4.51 and a 52 week high of $14.38. The stock has a fifty day moving average price of $8.47 and a two-hundred day moving average price of $10.14.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.